INVO Fertility Inc
invofertility.comWhat Do They Do?
Operates fertility clinics that provide fertility services, including IVF and intravaginal culture, and sells INVOcell devices to third-party fertility clinics.
10-K for FY2025, filed Jun 2, 2026
How Do They Make Money?
The clinics earn revenue from fertility and lab services when those services are performed; INVOcell sales to third-party fertility clinics are earned when the devices ship.
10-K for FY2025, filed Jun 2, 2026Revenue generated from clinical and lab services related at the Company’s fertility clinics is typically recognized at the time the service…View ↗
Revenue generated from the sale of INVOcell is typically recognized at the time the product is shipped, at which time the title passes to…View ↗
Historically, our approach to marketing INVOcell was focused on identifying partners within targeted geographic regions that we believe…View ↗
-
10-K for FY2025, filed Jun 2, 2026
FY2025 revenue by product or service ↗
$6.8M
-
10-K for FY2025, filed Jun 2, 2026
$6.8M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Clinic Revenue
Sold outright
10-K for FY2025, filed Jun 2, 2026 |
98%
FY2022: 75%
|
Clinic Revenue, FY2025
$6.7M Sources
|
Sold outright |
|
Product
Sold outright
|
1.8%
FY2022: 25%
|
Product, FY2025
$120.2K Sources
|
Sold outright |
Who Are Their Customers?
Patients receive fertility care at the clinics, with visits generated through social media, obstetrician-gynecologist referrals and word of mouth. INVO sells INVOcell directly to third-party IVF clinics.
10-K for FY2025, filed Jun 2, 2026
Do Revenues Turn Into Profits?
No. It lost $23.3M in FY2025.
10-K for FY2025, filed Jun 2, 2026
−$7.2MView ↗
10-K for FY2025, filed Jun 2, 2026
−$23.3MView ↗
10-K for FY2025, filed Jun 2, 2026
−$7.1MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
$888.7KView ↗
- ▲ Now profitable
- vs −$3.6M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 14, 2026
Open tableView ↗
-
Jun 25, 2026
Acquired full ownership of Birmingham fertility clinic
The acquisition converted the clinic from a joint venture into a wholly owned subsidiary.
Sources
8-K, filed Jun 25, 2026
On June 23, 2026, the Company consummated the acquisition (the “Acquisition”) of one-hundred percent (100%) of the membership interests of…View ↗
Growing. Revenue grew 64% in 4 years, from $4.2M in FY2021 to $6.8M in FY2025, about 13% a year.
Greater focus on clinic operations
The earlier report centered on the INVOcell device and dedicated INVO Centers; the latest frames acquiring, establishing and operating fertility clinics as the principal strategy, while retaining device sales.
10-K for FY2022, filed Apr 17, 2023 10-K for FY2025, filed Jun 2, 2026We are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology (“ART”) marketplace by making…View ↗
Who Do They Compete With?
Competes with Anecova and invoLab
10-K for FY2025, filed Jun 2, 2026The only ART medical device competitors for INVOcell that we are aware of are intrauterine devices called AneVivo™, developed by Anecova…View ↗
Loading...
